Ubrogepant
CAS 1374248-77-7 5 FDA-DMF suppliersSmall Molecule
Overview
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine with or without aura in adults. It offers a new mechanism for migraine relief by targeting the CGRP pathway.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Ubrogepant expires 22 Dec 2041. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Migraine
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.